News Background

Oxford, UK – 11 June 2010. OGT, provider of innovative genetics and biomarker solutions to advance molecular medicine, today announced that the management system at its Oxford, UK headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI), one of the world’s leading certification bodies. The scope of certification includes the design and provision of OGT’s CytoSure®, Genefficiency™ and biomarker discovery products and services, and demonstrates the company’s commitment to providing the highest quality solutions and customer service.

The ISO 9001:2008 standard promotes a process approach to quality management that focuses on fully meeting customer requirements, measuring customer satisfaction and achieving continual improvement. Dr Mike Evans, OGT’s CEO, commented: “ISO 9001 certification is part of a wider programme of initiatives that we are conducting to gain independent endorsement of our methods.  We recently became the first company to be named as a High-Throughput Certified Service Provider for Agilent microarrays, and these initiatives put us at the forefront of the growing genomic research and clinical diagnostic products and services markets. ISO 9001 registration underpins the commitment of our talented and experienced team to designing and providing high quality products and services.”

ISO 9001:2008 certification followed an assessment by BSI, requiring on-site audit and examination of OGT's documented procedures and operations, including product design and development processes. The OGT Management System will subsequently be monitored through OGT’s own internal audit procedures and by periodic surveillance audits by the certification body. 

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

You might also be interested in

OGT celebrates opening of new Cambridge site Listing Image

OGT celebrates opening of new Cambridge site

06 Jun 2019

State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.

Read
NHS study confirms higher reporting rate for OGT's CytoSure v3 array Listing Image

NHS study confirms higher reporting rate for OGT's CytoSure v3 array

22 Jul 2020

Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.

Read
OGT expands custom NGS cancer panel content Listing Image

OGT expands custom NGS cancer panel content

12 Jun 2018

Increased NGS content, now covering 120 fully optimised cancer related genes, provides even more flexibility for customisation.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter